Keymed Stages $378 Million Hong Kong IPO for Antibody Portfolio
July 09, 2021 at 04:46 AM EDT
Keymed Biosciences of Chengdu completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidates. The company priced the IPO at the top end of the range, and its shares rose 28% in its first trading session. Founded in 2016, Keymed is developing nine products for autoimmune and cancer indications. It has developed an innovative antibody discovery platform consisting of monoclonal antibodies, antibody drug conjugates and bispecific antibodies that use its proprietary T cell engager bispecific antibody platform. More details.... Stock Symbol: (HK: 2162) Share this with colleagues: // //
